An investigational triple agonist of the GIP, GLP-1 and glucagon receptors, in late-stage trials for obesity.
Retatrutide is Eli Lilly's experimental once-weekly injection that activates three receptors: GIP, GLP-1 and glucagon. Adding glucagon activity is intended to raise energy expenditure on top of the appetite effects of the incretin drugs.
Retatrutide is not approved anywhere. Lilly has said it plans to submit an application to FDA in the first quarter of 2027, so approval, if it comes, is unlikely before late 2027. Anything sold as retatrutide today is not a legitimate product.
Status reflects public FDA actions and reporting as of October 8, 2026. An advisory committee vote is a recommendation, not an FDA decision, and inclusion on a compounding list is not FDA approval.
A phase 2 trial published in 2023 reported larger average weight loss than earlier incretin drugs had shown at similar time points. The phase 3 TRIUMPH program is ongoing, with topline results reported during 2026.
nnng.com does not publish doses, cycles or protocols for peptides. For approved drugs, the dose comes from the FDA-approved prescribing information and your prescriber. For unapproved compounds there is no established human dose, and numbers that circulate online are usually extrapolated from animal studies or written by sellers. If a clinician has already prescribed a dose, our reconstitution calculator converts that prescribed amount into syringe units. It is arithmetic only and does not suggest a dose.